ESR1 and triple-negative breast carcinoma: Moreover, estrogen receptor (ER), progesterone receptor (PR), and HER-2 are the main targets for targeted therapy in breast cancer, and samples/cases that are negative for these three receptors are defined as triple negative breast cancer (TNBC), which comprises about 15% of breast cancer cases.